Syk, or spleen tyrosine kinase, is a highly expressed cytosolic non-receptor protein tyrosine kinase (PTK) found in both hematopoietic and non-hematopoietic cells, including mast cells, B lymphocytes, T lymphocytes, neutrophils, dendritic cells, and macrophages.
Syk mediates important signal transduction pathways after immune cell receptors are activated. In addition to osteoclasts and breast cancer cells, Syk binds to various receptors on the surface of a wide range of cells, including B cells, mast cells, monocytes, macrophages, and neutrophils. SYK is activated after these receptors are activated by their ligands and orchestrates a variety of cellular responses, including the production of cytokines (in T cells and monocytes) and phagocytosis (in macrophages).
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V111571 | (rel)-PRT062607 | 1194954-52-3 | (rel)-PRT062607 ((rel)-P505-15) is the relative configuration of PRT062607. |
|
V129486 | As48 | 1214405-38-5 | As48 is a selective TREM2 agonist with a KD value of 12.48 μM in TRIC binding assays. |
|
V88080 | Asebogenin | 520-42-3 | Asebogenin has anti-malarial activity in vitro. |
|
V130129 | BI 894416 | 1810059-82-5 | BI 894416 is a spleen tyrosine kinase (SYK) inhibitor. |
|
V133300 | DBMB | 314027-66-2 | DBMB is a spleen tyrosine kinase (Syk) inhibitor that can significantly inhibit the activity of Syk kinase. |
|
V136985 | GT103 | GT103 is a human monoclonal antibody that targets complement factor H (CFH). | |
|
V137762 | Ibt-DOX | Ibt-DOX is a BTK inhibitor with an IC50 value of 2.89 nM. | |
|
V115509 | IQS-019 | 1630804-24-8 | IQS-019 is a B cell receptor (BCR) kinase inhibitor. |
|
V88079 | MK-8457 | 1312518-84-5 | MK-8457 is a dual SYK/ZAP70 inhibitor. |
|
V140486 | MTX-216 | 1952236-19-9 | MTX-216 is a dual ATP-competitive inhibitor of PI3K and EGFR. |
|
V88078 | NMS-0963 | 2765304-82-1 | NMS-0963 (compound 1) is an orally active spleen tyrosine kinase (SYK) inhibitor with an IC50 of 3 nM. |
|
V2680 | PRT-060318 | 1194961-19-7 | PRT-060318 (also known as PRT318) is a novel, potent,selective inhibitor of the Syk tyrosine kinase, as an approach to HIT treatment. |
|
V112026 | PRT-060318 dihydrochloride | 3032567-93-1 | PRT-060318 (PRT318) dihydrochloride is a potent, selective, and orally effective tyrosine kinase Syk inhibitor with an IC50 of 3 nM. |
|
V0652 | PRT062607 (P505-15, BIIB057) HCl | 1370261-97-4 | PRT062607 (also known as P505-15, BIIB-057) HCl is a novel, potent, highly selective and orally bioavailablesmall molecule Syk inhibitor with potential anti-inflammatory activity. |
|
V2390 | SRX3207 | 2254693-15-5 | SRX-3207 (SRX3207) is a novel, potent, orally bioactive and dual inhibitor of Syk-PI3K withanti-tumor activity. |
|
V69783 | Syk Inhibitor II dihydrochloride | 227449-73-2 | Syk Inhibitor II di-HCl is a specific and ATP-competitive Syk inhibitor (antagonist) with IC50 of 41 nM. |
|
V88081 | Syk Inhibitor II hydrochloride | 2490508-82-0 | Syk Inhibitor II hydrochloride is a potent, highly selective and ATP-competitive Syk inhibitor with IC50 of 41 nM. |
|
V145484 | Syk-IN-13 | 1360905-04-9 | Syk-IN-13 is a Syk inhibitor that may be used in research on rheumatoid arthritis and/or systemic lupus erythematosus. |
|
V51506 | SYK/JAK-IN-1 | 2737326-28-0 | SYK/JAK-IN-1 is a dual SYK/JAK inhibitor (antagonist) with IC50 of <5 nM for SYK and JAK2 respectively. |
|
V117100 | T2M-010 | 364611-21-2 | T2M-010 is a potent TREM2 agonist that can cross the blood-brain barrier (Kd = 0.83 μM). |